High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders

(2015) Kamilla W. Miskowiak et al.   BIOLOGICAL PSYCHIATRY

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

(2015) Daniel Ontaneda et al.   LANCET NEUROLOGY

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability

(2015) C. H. Polman et al.   NEUROLOGY

Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis

(2014) Fatemeh Najmi Varzaneh et al.   ACTA NEUROLOGICA BELGICA

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Targeting erythropoietin for chronic neurodegenerative diseases

(2013) Zhao Zhong Chong et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: A pilot, open-label study with neurophysiological measurements

(2013) A. Créange et al.   NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY

Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial

(2013) Kamilla W Miskowiak et al.   NEUROPSYCHOPHARMACOLOGY

Unknown

(2012) Nora Hagemeyer et al.   MOLECULAR MEDICINE

Is there a deleterious effect of erythropoietin in end-stage renal disease?

(2011) Ajay K. Singh   KIDNEY INTERNATIONAL

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

(2011) DW Langdon et al.   Multiple Sclerosis Journal

Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia

(2010) T Wüstenberg et al.   MOLECULAR PSYCHIATRY

Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice

(2009) Michael Thorne et al.   JOURNAL OF NEUROIMMUNOLOGY

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

(2009) Hannelore Ehrenreich et al.   STROKE